What does the US Myriad decision on unpatentability of genes mean for other natural products?

14 August 2013

In July, the US Supreme Court held that isolated DNA sequences are not patentable inventions. This overturned years of established practice by the US Patent and Trademark Office, and pulled the rug out from under many gene patents.

Mewburn Ellis partner Emily Hayes reviews the impact of the US Supreme Court's decision in the Myriad case in this article published in the August issue of Chemistry & Industry magazine, published by the Society of Chemical Industry.

____________________________________



Looking for something specific?